Expenditures for glaucoma medications appear to have increased

June 13, 2011

In recent years, spending for glaucoma medications has increased, especially for women, persons who have only public health insurance and those with less than a high school education, according to a report published Online First by Archives of Ophthalmology, one of the JAMA/Archives journals.

Glaucoma is a condition marked by damage to the , and is a leading cause of blindness. According to background information in the article, approximately 2.2 million individuals ages 40 years and older in the United States currently have primary open-angle ; this number is expected to increase by almost 50 percent by 2020. Presently, the direct annual medical costs associated with the condition are roughly $2.9 billion. Although data on glaucoma-expense trends is limited, the authors note that "there is a direct correlation between increased expenditure and increased severity of glaucoma, with medication consisting of one-third to one-half of direct costs."

To study current trends in glaucoma-related medication expenditures, Byron L. Lam, M.D., from the Bascom Palmer Eye Institute in Miami, and colleagues examined data from the Medical Expenditure Panel Survey from 2001 to 2006. Beginning in 2006, these data included information about participation in the Medicare Part D . The analysis included 1,404 patients ages 18 years and older who had used glaucoma medication.

The authors found that in 2001, the average expenditure per patient for glaucoma medication was $445; by 2006, this amount had increased to $557. Significant increases appeared among women, those who had not completed high school and those who had only public health insurance. Additionally, average spending for prostaglandin analog medications increased from $168 in 2001 to $271 in 2006; during the same period, average spending for decreased from $167 to $69. In comparison with individuals who had , glaucoma medication expenditure among those with coverage was higher.

The authors explain that as the country's population ages and encompasses more patients with glaucoma, spending for drugs to treat the condition is likely to increase. "The results of our study as well as an understanding of the factors that account for the increase in glaucoma medication expenditure are important to help develop effective strategies and protocols for the medical management of glaucoma that optimize treatment and control expenditures," they write. Further study to explain the trends among patient subgroups is needed, the authors conclude.

More information: Arch Ophthalmol. 2011;doi:10.1001/archophthalmol.2011.142

Related Stories

Recommended for you

Zika in fetal brain tissue responds to a popular antibiotic

November 30, 2016

Working in the lab, UC San Francisco researchers have identified fetal brain tissue cells that are targeted by the Zika virus and determined that azithromycin, a common antibiotic regarded as safe for use during pregnancy, ...

Zika and glaucoma linked for first time in new study

November 30, 2016

A team of researchers in Brazil and at the Yale School of Public Health has published the first report demonstrating that the Zika virus can cause glaucoma in infants who were exposed to the virus during gestation.

Flu forecasts successful on neighborhood level

November 30, 2016

Scientists at Columbia University's Mailman School of Public Health developed a computer model to predict the onset, duration, and magnitude of influenza outbreaks for New York City boroughs and neighborhoods. They found ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.